Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01977911
Other study ID # UCL RD & ID no. 12/0331
Secondary ID 2013-004359-18
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date April 2018
Est. completion date May 25, 2018

Study information

Verified date June 2018
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to test a new groundbreaking treatment for narrowing of the voicebox and upper windpipe, which can be due to injury, inflammatory disease or cancer treatment. Narrowing of the voicebox or upper windpipe can leave patients dependant on a tracheostomy tube to breath through (a tube or hole in the neck), which can require a high level of care with regular hospital visits and can lead to recurrent chest infections. Regular surgical procedures may be necessary to widen the airway. Speaking may be very difficult or not even possible, breathing is usually a struggle and swallowing can also be affected. Patients feel very tired all the time.

The new treatment tested by this study is an implant that will partially replace the voicebox or upper windpipe in order to cure the narrowing. The implant is based on a human donor voicebox or windpipe that has been processed with detergents and enzymes in order to remove all the cells from the donor, leaving a 'scaffold' of connective tissue. The patient's own stem cells are removed from the bone marrow, then are grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. A split skin graft from the patient may be needed to line the inside of the implant. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'.

Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient, and an operation is performed which occurs in two separate stages. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it. Patients will be followed up for two years after this operation, with investigations such as CT scans, examination of the voicebox and windpipe with a flexible camera (bronchoscopy) and blood tests performed at specific times.

It is intended that this treatment will significantly improve patients' symptoms resulting in better breathing, swallowing and voice function, reducing the need for repeated hospital visits and procedures and enhancing patients' quality of life.


Description:

The RegenVOX trial is a phase I/IIa safety and potential efficacy clinical trial of tissue-engineered laryngotracheal replacement using autologous-derived cells and decellularised human donor scaffolds in 10 patients with severe acquired laryngotracheal stenosis.

Current solutions for the treatment of advanced structural disorders of the larynx such as trauma, inflammatory disorders or following cancer treatment are suboptimal and patients with such problems require frequent hospitalisation. A regenerative solution that restores the anatomy of the larynx would provide a definitive treatment for these patients, improve the outcome of resection for malignant disease, avoid some laryngectomies and would reduce the threshold for performing surgery over administering chemotherapy thereby reducing morbidity. Giving patients a once-only therapy of a life-time functional living replacement would allow patients to lead tracheostomy-free lives with improved breathing, swallowing and speech and a lower requirement for hospital follow-up.

This project is a clinical trial of tissue engineered partial laryngeal replacements in 10 patients with end-stage laryngeal stenosis. The intervention is based on a human donor graft scaffold which is decellularised and then seeded with autologous mesenchymal stem cell-derived chondrocytes externally. Following expansion of these cells ex-vivo, the graft is implanted. This is the first clinical trial to our knowledge of a stem-call based organ replacement.

Inclusion criteria are:

Patients aged >=18 years with sufficient numbers of Mesenchymal Stromal Cells (MSCs) in their human Bone Marrow (hBM) aspirate.

Patients with Myer-Cotton Grade 3 or 4 laryngotracheal stenosis or malacia due to traumatic, inflammatory, iatrogenic, or idiopathic causes who have exhausted conventional therapies.

Exclusion criteria are:

Pregnancy. Patients positive for HIV 1, HIV 2, Hepatitis C (HCV), Hepatitis B (HBV), syphilis or Human T-cell Lymphotropic Virus (HTLV).

Those unable to provide informed consent. Co-morbid severe chronic obstructive pulmonary disease (according to NICE criteria) Patients with active / uncontrolled chronic inflammatory conditions such as granulomatosis with polyangitis (formerly Wegener's granulomatosis) and sarcoidosis.

Any current or previous cancer within 5 years (except non-melanoma skin cancer, adequately treated carcinoma in situ of the uterine cervix, laryngeal malignancy treated locally with no local recurrence and no metastases, or low grade airway malignancy such as chondrosarcoma which may be causing airway obstruction).

Life expectancy less than 5 years unless this limitation is principally due to the airway obstruction to be treated.

Concurrent enrollment in any other Clinical Trial of Investigational Medicinal Product (CTIMP).

The primary outcome measure is safety as determined by morbidity and mortality as measured by occurrence of adverse events. Secondary outcome is efficacy as determined by

1. Absence of tracheostomy.

2. Absence of non-absorbable stent.

3. Improvement in mean airway diameter.

4. Improvement in Forced Expiratory Volume in 1 second (FEV1).

5. Improvement in global quality of life (EQ-5D).

6. Improvement in maximum phonation time (MPT) as measured by Voice Analysis Operavox (VAO).

7. Improvement in self assessment of voice handicap (VHI-10).

8. Improvement in swallowing function (EAT-10).

9. Improvement in airway, dyspnoea, voice, swallowing index (ADVS index).

10. Improvement in the penetration-aspiration scale (PAS) as per Video Fluoroscopic Swallow (VFS) or Functional Endoscopic Evaluation of Swallowing (FEES).

Health economics. Patients will be followed up for 2 years within this study. Key milestones will be assessed at 6 and 12 months. The follow-up regimen includes bronchoscopy and airway brushings taken at 1 week post implantation and full physical assessment including CT imaging, pulmonary function tests, blood tests and bronchoscopy at 1, 6, 12, 18 and 24 months. Telephone follow-up will take place in between these assessments.

This trial will provide a level of insight into the real clinical potential for stem cell/tissue engineering combined technologies. The results will have wide implications for the development of hollow organ- replacements such as those for oesophagus, bowel and vascular disorders. We will also develop new pathways for maximising discovery science and health economic benefit from complex regenerative medicine therapies (a reverse translational route map), with important generic benefits for scientists and clinicians.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 25, 2018
Est. primary completion date May 25, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Patients aged >=18 years with sufficient numbers of Mesenchymal Stromal Cells (MSCs) in their 8-10ml human Bone Marrow (hBM) aspirate.

Patients with Myer-Cotton Grade 3 or 4* laryngotracheal stenosis or equivalent due to traumatic, inflammatory, iatrogenic, or idiopathic causes who have exhausted conventional therapies.

*The Myer-Cotton grading system for mature, firm, circumferential stenosis, confined to the subglottis describes the stenosis based on the per cent relative reduction in cross-sectional area of the subglottis. Four grades of stenosis:

- grade 1 lesions have less than 50% obstruction

- grade 2 lesions have 51% to 70% obstruction

- grade 3 lesions have 71% to 99% obstruction

- grade 4 lesions have no detectable lumen or complete stenosis

Exclusion Criteria:

- Pregnancy

- Patients positive for HIV 1, HIV 2, HCV, HBV, syphilis or HTLV

- Those unable to provide informed consent

- Co-morbid severe chronic obstructive pulmonary disease (according to NICE criteria)

- Patients with active / uncontrolled chronic inflammatory conditions such as granulomatosis with polyangitis (formerly Wegener's granulomatosis) and sarcoidosis

- Any current or previous cancer within 5 years (except non-melanoma skin cancer, adequately treated carcinoma in situ of the uterine cervix, laryngeal malignancy treated locally with no local recurrence and no metastases, or low grade airway malignancy such as chondrosarcoma which may be causing airway obstruction)

- Life expectancy less than 5 years unless this limitation is principally due to the airway obstruction to be treated

- Concurrent enrollment in any other Clinical Trial of Investigational Medicinal Product (CTIMP).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Stem cell based tissue engineered partial laryngeal implants
Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.

Locations

Country Name City State
United Kingdom University College London NHS Foundation Trust (UCLH) London

Sponsors (2)

Lead Sponsor Collaborator
University College, London Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Hamilton N, Bullock AJ, Macneil S, Janes SM, Birchall M. Tissue engineering airway mucosa: a systematic review. Laryngoscope. 2014 Apr;124(4):961-8. doi: 10.1002/lary.24469. Epub 2013 Nov 19. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Cost effectiveness of tissue engineered laryngotracheal replacement We will also develop new pathways for maximising discovery science and health economic benefit from complex regenerative medicine therapies (a reverse translational route map), with important generic benefits for scientists and clinicians. 24 months post operative follow up
Primary Safety of tissue engineered laryngotracheal replacement The primary outcome measure is safety of the tissue engineered implant as defined by morbidity and mortality and measured by occurrence of adverse events throughout 24 months post operative follow up 24 months post operative follow up
Secondary Efficacy of tissue engineered laryngotracheal replacement Secondary outcome is efficacy as determined
Absence of tracheostomy.
Absence of non-absorbable stent.
Improvement in mean airway diameter.
Improvement in Forced Expiratory Volume in 1 second (FEV1).
Improvement in global quality of life (EQ-5D).
Improvement in maximum phonation time (MPT) as measured by Voice Analysis Operavox (VAO).
Improvement in self assessment of voice handicap (VHI-10).
Improvement in swallowing function (EAT-10).
Improvement in airway, dyspnoea, voice, swallowing index (ADVS index).
Improvement in the penetration-aspiration scale (PAS) as per Video Fluoroscopic Swallow (VFS) or Functional Endoscopic Evaluation of Swallowing (FEES).
Health Economics
24 months post operative follow up
See also
  Status Clinical Trial Phase
Suspended NCT02949414 - A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells Phase 1
Not yet recruiting NCT03411928 - Endotracheal Dilator to Improve Oxygenation N/A
Recruiting NCT05028023 - Tracheal Dilatation in Pediatric Patients With Acquired Tracheal Stenosis, and the Effects of Apneic Oxygenation N/A
Completed NCT02796326 - Modified Endotracheal Balloon Dilator to Improve Patient Oxygenation and Allow Ventilation During Airway Procedures N/A
Completed NCT06121024 - Long-term Outcomes of Post-intubation Tracheal Stenosis; 7-year Follow-up
Recruiting NCT02961387 - A Clinical Trial on Effectiveness and Safety of Hydrogen Generator to Treat Dyspnea for the Patients With Tracheal Stenosis: A Randomized, Double-blind and Single-center Clinical Study N/A
Completed NCT02855502 - Investigation of the Effect of Systemic Steroids on Treatment and Prevention of Recurrent Tracheal Stenosis in Postoperative Patients Phase 4
Completed NCT04674995 - Stent Versus Balloon Dilatation in Patients With Tracheal Benign Stenosis
Completed NCT01331863 - Airway and/or Pulmonary Vessels Transplantation Phase 1/Phase 2
Not yet recruiting NCT05835713 - Total Intravenous Anesthesia for Rigid Bronchoscopy Using Remimazolam N/A
Suspended NCT02620319 - Biodegradable Stents in the Management of Stenoses of the Large Airways N/A
Recruiting NCT03455881 - Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients
Recruiting NCT04719845 - DilAtation Versus Endoscopic Laser Resection in Simple Benign trAcheal sTEnosis N/A
Completed NCT05317923 - Airway Management During Unusual Tracheal Stenosis N/A
Enrolling by invitation NCT05535803 - Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells Phase 2
Completed NCT00705848 - Matrix Biology of Tracheobronchomalacia and Tracheal Stenosis N/A
Completed NCT03130374 - Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells Phase 1/Phase 2
Completed NCT06061380 - Challenges and Management of Post-intubation Tracheal Stenosis
Not yet recruiting NCT04625400 - Role of Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis N/A
Enrolling by invitation NCT04850742 - Feasibility of Tracheobronchial Reconstruction Using Bioengineered Aortic Matrices N/A